Akums Drugs and Pharmaceuticals Limited announced on January 23, 2026, that it has received European Good Manufacturing Practice (EU GMP) certificates for its two facilities located in Haridwar, Uttarakhand. Plant 1's certification is a renewal of its existing EU-GMP approval, while Plant 2 has obtained this certification for the first time. The certifications were issued by the BDA – Bulgarian Drug Agency. These accreditations are significant as they will enable Akums to cater to EU-regulated markets and explore new business opportunities in EU countries and other markets that adhere to EU-GMP regulations. Specifically, Plant 1 is now authorized to manufacture and supply tablets, hard gelatine capsules, and sachet dosage forms for EU countries. Plant 2 is authorized to manufacture and supply oral liquid formulations for EU countries. The company also mentioned that a European CDMO contract, signed in December 2024, will be serviced from Plant 2. The validity period for these approvals is three years, extending until October 2028. The company has confirmed that there is no withdrawal, cancellation, or suspension of any license or approval.
